Healthcare

CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations

Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s...

Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in...

Magnolia Medical Launches New Magnolia Analytics™ Service to Streamline Data Capture and Quantify the Clinical & Cost Effectiveness of Preventing Sepsis Misdiagnosis

This unique, proprietary service is exclusively available to Magnolia Medical customers as part of its Mission to ZERO® standards change...

Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units

CHICAGO, IL / ACCESSWIRE / June 27, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...

error: Content is protected !!